Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused on weight management. The collaboration connects Noom users with Eli Lilly’s ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

Both Zepbound-maker Eli Lilly and Wegovy ... whether to treat diabetes or maintain weight loss. But a study earlier this year found 65% of those without diabetes discontinued the drugs in less ...

Rosie O'Donnell said she’s lost more weight since taking Mounjaro for her diabetes, admitting that she feels healthier and her new clothing size is “shocking.” ...

But there are many questions left to answer, not least what the future holds for weight-loss medications and society at large ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes ...